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Latent membrane protein 2A (LMP2A) of latent Epstein–Barr virus (EBV) specifically associates with HECT domain-
containing Nedd4-family ubiquitin-protein ligases (E3s). Here we demonstrate that LMP2A is specifically ubiquitinated by the
HECT domains of AIP4 and WWP2. Deletion and site-specific mutation of LMP2A indicates that LMP2A is ubiquitinated at
its amino-terminus and is not ubiquitinated on lysine residues. LMP2A and LMP1, also encoded by EBV, are two of only foure amin
nce (USAINTRODUCTION
Ubiquitination of proteins is a posttranslational modi-
fication in which a 76 amino acid polypeptide, ubiquitin,
or a multiubiquitin chain, is attached to proteins tagging
them for degradation (Hershko and Ciechanover, 1998).
Ubiquitination is catalyzed by the sequential actions of
the ubiquitin-activating enzyme (E1), ubiquitin-conjugat-
ing enzyme (E2), and ubiquitin-protein ligase (E3). The E1
first activates ubiquitin in an ATP-dependent reaction by
forming a thioester bond at its active-site cysteine with
the carboxy-terminus of ubiquitin. Activated ubiquitin is
next transferred to an active site cysteine of the E2. The
E3 is bound to the targeted substrate and catalyzes the
covalent attachment of ubiquitin to the -amino group of
a lysine residue of the substrate. The generation of
multiubiquitin chains is mediated by the repeated attach-
ment of ubiquitin onto a lysine residue of ubiquitin. E3s
play an essential role in specific substrate recognition.
They are defined as proteins or protein complexes that
include RING-finger-containing E3s (Freemont, 2000)
and HECT-domain containing E3s (Huibregtse et al.,
1995). The HECT family E3s are the only known E3s that
form ubiquitin-thioester intermediates and directly cata-
lyze substrate ubiquitination. Nedd4-family E3s belong to
the HECT domain family and their binding specificity for
target proteins is contained within a C2 domain and two
to four repeats of a WW domain (Harvey and Kumar,
1999).
Ubiquitination commonly occurs within internal lysine
residues; however, recent studies revealed that ubiquitin
conjugation can occur at the -amino group of amino-
terminal residue. Substitution of all lysine residues in153MyoD (Breitschopf et al., 1998), LMP1 (Aviel et al., 2000),
and E7 (Reinstein et al., 2000) does not affect signifi-
cantly their conjugation and degradation in the ubiquitin
pathway. In contrast, extension of amino-terminus by the
addition of a few amino acids makes all the proteins
stable, indicating the microenvironment of the amino-
terminus is important for their ubiquitination and subse-
quent degradation. However, the mechanism of ubiquitin
conjugation at amino-terminal residue, especially by
specific E3s, is unclear.
Epstein-Barr virus (EBV) is a ubiquitous human onco-
genic herpesvirus associated with numerous prolifera-
tive disorders, including Burkitt’s lymphoma (BL),
Hodgkin’s disease (HD), AIDS-associated immunoblastic
lymphoma, oral hairy leukoplakia (OHL), and nasopha-
ryngeal carcinoma (NPC) (Kieff, 1996; Longnecker, 1998).
B lymphocytes infected with EBV in vitro are immortal-
ized and subsequently termed lymphoblastoid cell lines
(LCLs). These EBV-transformed LCLs express a re-
stricted set of latency-associated viral products, includ-
ing six EBV nuclear antigens (EBNAs), three latent mem-
brane proteins (LMP1, LMP2A, and LMP2B), two small
RNAs (EBERs), and BamHI A rightward transcripts
(BARTs). In healthy individuals, EBV typically establishes
a persistent latent infection in peripheral B lymphocytes.
These latently infected cells express only LMP2A,
EBNA1, and BARTs (Chen et al., 1999; Thorley-Lawson,
2001). Further, LMP2A is expressed in tumor cells in
several EBV-associated malignancies including NPC and
HD (Kieff, 1996; Longnecker, 1998; Thorley-Lawson,
2001).
LMP2A is a 12 transmembrane-spanning integral
membrane protein that localizes in lipid rafts in EBV-
immortalized LCLs (Dykstra et al., 2001; Longnecker,proteins that have been identified that are ubiquitinated at th
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protein interactions, including eight tyrosine residues
and two PY motifs. LMP2A functions to down-regulate B
cell receptor (BCR)-mediated signal transduction and
viral activation from latency by recruitment and constitu-
tive phosphorylation of protein-tyrosine kinases (PTKs)
such as Lyn and Syk (Fruehling and Longnecker, 1997;
Fruehling et al., 1998; Miller et al., 1995). LMP2A also
acts to provide B cells with both a survival and a devel-
opmental signal in vivo (Caldwell et al., 1998). Previously,
we have shown that the level of LMP2A transcripts cor-
relates with the severity of the LMP2A in vivo phenotype,
suggesting that LMP2A function may be regulated by the
amount of LMP2A (Caldwell et al., 2000). Recently, we
have shown that LMP2A specifically associates with
Nedd4-family ubiquitin-protein ligases (E3s), including
AIP4, WWP2, and Nedd4. This interaction is important in
regulating protein stability and phosphorylation of
LMP2A and LMP2A-associated proteins (Ikeda et al.,
2000; Winberg et al., 2000). The studies in the current
article demonstrate that LMP2A is ubiquitinated at the
amino-terminus by Nedd4-family E3s and not at lysine
residues.
RESULTS
LMP2A is ubiquitinated by the HECT-domain of
Nedd4-family E3s
Our recent studies have shown that LMP2A specifi-
cally associates with Nedd4-family E3s, suggesting that
LMP2A is directly conjugated by ubiquitin which targets
it for degradation. To detect LMP2A ubiquitination in
cells, we cotransfected the EBV-negative B lymphoma
cell line BJAB with LMP2A, Nedd4-family E3s, and HA-
tagged ubiquitin expression plasmids and identified ubi-
quitinated products by blotting anti-LMP2A immunopre-
cipitates with anti-HA antibody. To confirm the role of the
binding of the Nedd4-family E3s AIP4 and WWP2 to
LMP2A in LMP2A ubiquitination, AIP4 or WWP2 was
cotransfected with the LMP2A PY mutant (PY1PY2) in
which both the PY motifs (PPPPY) are mutated to PAAPY.
This LMP2A-PY1PY2 mutant does not bind to the WW
domains of Nedd4-family E3s in vitro and in vivo (Ikeda et
al., 2000, 2001). As shown in Fig. 1, AIP4 and WWP2
catalyzed the ubiquitination of wild-type LMP2A as ob-
served by the presence of high molecular weight ladder
bands of ubiquitin conjugates that were readily observed
in LMP2A and HA-tagged ubiquitin transfected cells (Fig.
1, HA and LMP2A Blot, lanes 2 and 5). These same
complexes were not observed when the cells were
transfected only with the HA-tagged ubiquitin (Fig. 1,
lanes 1 and 4) or when the LMP2A PY motifs are mutated
(Fig. 1, HA Blot, lanes 3 and 6). A densitometric analysis
revealed that the ubiquitination of PY mutant LMP2A was
38-fold less with AIP4 and 142 times less with WWP2,
when compared to wild-type LMP2A, although mutant
LMP2A expression was two times less than wild-type.
The somewhat reduced level of LMP2A-PY1PY2 protein
in the LMP2A blot when compared to wild-type LMP2A is
a result of experimental variation likely due to differences
in transfection efficiency since it was not routinely ob-
served. These results indicate that LMP2A is ubiquiti-
nated by exogenous E3s in BJAB cells and that the
LMP2A PY motifs are required for the ubiquitination of
LMP2A by AIP4 and WWP2.
Next, to confirm the role of Nedd4-family E3s in
LMP2A ubiquitination, the active-site cysteine of the
HECT domain, C823 in WWP2, was mutated to alanine to
create a dominant-negative form WWP2. This mutant will
retain binding to LMP2A since the WW domains within
WWP2 will be unaltered and this is the region critical for
binding of WWP2 to the LMP2A PY motifs (Ikeda et al.,
2000). When compared with WWP2, the dominant-nega-
tive C823A did not direct LMP2A ubiquitination (Fig. 2,
HA and LMP2A Blot, compare lanes 3 and 4), indicating
that the cysteine-to-alanine mutation completely blocked
the activity of the WWP2 HECT domain. Interestingly,
mutation of the WWP2 HECT domain resulted in a de-
crease in WWP2 ubiquitination (Fig. 2, FLAG Blot, com-
pare lanes 3 and 4), suggesting that WWP2 may be
susceptible to autoubiquitination which may be impor-
tant for WWP2 degradation. Similar results were ob-
tained using AIP4 and a corresponding mutation in the
AIP4 HECT domain (data not shown).
FIG. 1. Ubiquitination of LMP2A PY motif mutant. BJAB cells were
transiently transfected with empty vector (lanes 1 and 4), LMP2A (lanes
2 and 5), or LMP2A PY mutant (lanes 3 and 6), with AIP4 (lanes 1 to 3),
or WWP2 (lanes 4 to 6), and with HA-Ub (lanes 1 to 6). LMP2A
immunoprecipitates were immunoblotted with anti-HA to detect ubiq-
uitin conjugates and whole lysates were immunoblotted with anti-
LMP2A to detect LMP2A expression. A densitometric analysis revealed
that the ubiquitination of PY mutant LMP2A was 38-fold less with AIP4
and 142 times less with WWP2 when compared to wild-type LMP2A,
although mutant LMP2A expression was two times less than wild-type.
Protein standards are indicated in kDa.
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Lysine-less LMP2A mutants are ubiquitinated by
Nedd4-family E3s
Target proteins are commonly ubiquitin-conjugated to
internal lysine residues by specific E3s. The LMP2A
amino acid sequence includes three lysine residues:
K177 and K349 are located in cytosolic domain, and K381
is located in extracellular domain. To identify the sites
responsible for the ubiquitination of LMP2A, deletion
mutants were used in the transient ubiquitination assay.
Both 312–497 and 168–365 mutants contain one ly-
sine residue, while 168–497 does not contain any lysine
residues. Surprisingly, all of the three deletion mutants,
including the lysine-less 168–497 mutant, were ubiqui-
tinated in the transient ubiquitination assay (Fig. 3, HA
and LMP2A Blot, lanes 2–5). This clearly indicates that
nonlysine residues are involved in LMP2A ubiquitination.
To confirm the ubiquitination at nonlysine residue, we
constructed a site-directed mutant in which all of lysine
residues were changed to alanine (LMP2A Lys-less).
Similar to the results of deletion mutants, Lys-less
LMP2A was ubiquitinated by endogenous E3s such as
wild-type LMP2A (Fig. 4, HA Blot, lanes 1 and 2). More-
over, Lys-less LMP2A ubiquitination by WWP2 was sim-
ilar to that observed for wild-type LMP2A ubiquitination
(Fig. 4, HA Blot, lanes 3 and 4). Therefore, we conclude
that LMP2A is specifically ubiquitinated at nonlysine res-
idues by Nedd4-family E3s.
The amino-terminal microenvironment of LMP2A is
important for LMP2A ubiquitination
Although lysine is a common target site for ubiquitina-
tion, amino-terminal ubiquitination of MyoD, LMP1, and
E7 have recently been reported. In each case, the attach-
ment of a Myc-tag to the amino-terminus stabilized the
proteins (Aviel et al., 2000; Breitschopf et al., 1998; Rein-
stein et al., 2000). An amino-terminal deletion of LMP1
and E7 also stabilized the protein (Aviel et al., 2000;
Reinstein et al., 2000). These results suggest that the
microenvironment of amino-terminus is important for the
amino-terminal ubiquitination. To examine the role of the
LMP2A amino-terminal domain in ubiquitination, we con-
structed a series of amino-terminal mutants. The amino-
terminus of LMP2A contains three potential ATG codons
corresponding to amino acids M1, M6, and M9 of the
reported LMP2A sequence (Sample et al., 1989). This
region is relatively hydrophobic and conserved in the
FIG. 3. Ubiquitination of LMP2A deletion mutants. BJAB cells were
transiently transfected with empty vector (lane 1), LMP2A (lane 2),
LMP2A312–497 (lane 3), LMP2A168–365 (lane 4), LMP2A168–497
(lane 5), and with HA-Ub (lanes 1 to 6). LMP2A immunoprecipitates
were immunoblotted with anti-HA to detect ubiquitin conjugates (top)
and whole-cell lysates were immunoblotted with anti-LMP2A to detect
LMP2A expression (bottom). Protein standards are indicated in kDa.
FIG. 2. LMP2A ubiquitination by wild-type and dominant-negative
Nedd4-family E3s. BJAB cells were transiently transfected with empty
vector (lane 1) or LMP2A (lanes 2 to 4), WWP2 (lane 3), or C823A (lane
4), and with HA-Ub (lanes 1 to 4). LMP2A immunoprecipitates were
immunoblotted with anti-HA to detect ubiquitin conjugates and whole
lysates were immunoblotted with anti-LMP2A to detect LMP2A or
anti-FLAG to detect Nedd4-family E3 expression. Protein standards are
indicated in kDa.
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EBV homologues which infect monkeys and in different
EBV clinical isolates (Busson et al., 1995; Franken et al.,
1995; Rivailler et al., 1999). Analysis of the EBV genomic
nucleotide sequence indicates that the M1 and M6 se-
quences are perfectly matched to the Kozak sequence,
whereas the sequence surrounding M9 partially
matches the Kozak sequence (Kozak, 1986). Thus, each
of the ATGs may function as a start codon. To identify the
actual start codon for LMP2A, we constructed two ex-
pression plasmids containing cDNAs that would direct
LMP2A synthesis starting from either M1 or M9. The
LMP2A expression plasmid we used in Figs. 1 to 4
contains a cDNA starting from the M6 ATG. Moreover, a
His-tag or a Myc-tag was inserted just after M1 to
change the microenvironment of the LMP2A amino-
terminus. These mutations were incorporated into the
amino-terminus of the Lys-less LMP2A mutant to exclude
the possibility of ubiquitination at lysine residues. Ubiqui-
tination observed in M1-Lys-less LMP2A was similar to
that in M6-Lys-less LMP2A (Fig. 5A, HA Blot, lanes 1 and
2). However, M9-Lys-less LMP2A demonstrated an in-
crease in LMP2A ubiquitination compared with M1-Lys-
less LMP2A and M6-Lys-less LMP2A (Fig. 5A, HA Blot,
compare lanes 1 and 2 with lane 3). Interestingly, the
addition of the hydrophobic and positively charged His-
tag to the M1-Lys-less LMP2A resulted in LMP2A ubiq-
uitination that was similar to the parental M1-Lys-less
LMP2A (Fig. 5A, HA Blot, compare lanes 1 and 4). In
contrast, the addition of hydrophilic Myc-tag caused an
increase of LMP2A ubiquitination (Fig. 5A, HA Blot, com-
pare lane 5 with lanes 1 and 4). Similar results were
observed when each of these different LMP2A amino-
terminal constructs were tested using wild-type LMP2A
without the mutated lysines (data not shown). In addition,
AIP4 and WWP2 transient expression specifically in-
creased the ubiquitination of each of the LMP2A amino-
terminal constructs (data not shown). These results in-
dicate that the hydrophobic region of LMP2A amino-
terminus can be targeted for ubiquitination by Nedd4-
family E3s.
To understand the mechanism of LMP2A amino-termi-
nal ubiquitination, we attempted to determine the site of
initiation of LMP2A. To this end, the protein size of
LMP2A from EBV transformed LCLs was compared with
FIG. 4. Ubiquitination of LMP2A lysine-less mutant. BJAB cells were
transiently transfected with LMP2A (lanes 1 and 3), or LMP2A Lys-less
(lanes 2 and 4), with empty vector (lanes 1 and 2), or WWP2 (lanes 3
and 4), and with HA-Ub (lanes 1 to 4). LMP2A immunoprecipitates were
immunoblotted with anti-HA to detect ubiquitin conjugates (top) and
whole cell lysates were immunoblotted with anti-LMP2A to detect
LMP2A expression (bottom). Protein standards are indicated in kDa.
FIG. 5. Ubiquitination and molecular size of LMP2A amino-terminal
mutants. (A) BJAB cells were transiently transfected with M1-Lys-less
(lane 1), M6-Lys-less (lane 2), M9-Lys-less (lane 3), His-Lys-less (lane
4), or Myc-Lys-less (lane 5), and with HA-Ub (lanes 1 to 6). LMP2A
immunoprecipitates were immunoblotted with anti-HA to detect ubiq-
uitin conjugates and whole lysates were immunoblotted with anti-
LMP2A to detect LMP2A expression. (B) Lysates of LCL (lanes 1 and 5),
or BJAB transfectants of M1 (lane 2), M6 (lane 3), or M9 (lane 4) were
immunoblotted with anti-LMP2A. Protein standards are indicated in
kDa.
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LMP2A produced in transfected cells on a large SDS–
polyacrylamide gel. Figure 5B shows that LMP2A ex-
pressed from virus genome in EBV-transformed LCLs is
of identical size to the protein expressed from
LMP2A-M6 cDNA, indicating that the most abundant
form of LMP2A expressed in EBV-transformed LCLs is
initiated at M6 as long as the posttranslational modifica-
tion of LMP2A is similar in both EBV-transformed LCLs
and BJAB cells expressing LMP2A. LMP2A expressed in
BJAB cells has been shown to be functional (Miller et al.,
1993). These results suggest the amino-terminus of
LMP2A is important in the regulation of the amino-termi-
nal ubiquitination of LMP2A.
DISCUSSION
Ubiquitin conjugation of proteins is strictly regulated
by specific ubiquitin-protein ligase E3s. Here we show
that LMP2A associates with and is mono-, di-, and poly-
ubiquitinated by Nedd4-family E3s through the binding of
the two LMP2A PY motifs with the WW domains con-
tained in Nedd4-family E3s. We had previously shown
that mutation of the LMP2A PY motifs caused loss of
binding of the Nedd4-family E3s with LMP2A (Ikeda et
al., 2001). The mutation of the active site within the
WWP2 HECT domain, a Nedd4-family E3, resulted in the
inhibition of LMP2A ubiquitination, indicating that the
HECT domain is required for LMP2A ubiquitination. In
addition, we demonstrated that an LMP2A mutant in
which the three lysines contained within LMP2A were
mutated to alanine (lysine-less LMP2A) can be a sub-
strate of Nedd4-family E3s similar to the wild-type
LMP2A, indicating that nonlysine residues are the sites
of LMP2A ubiquitin conjugation. Finally, we determined
that the amino-terminal domain of LMP2A was critical for
LMP2A ubiquitination. Taken together, we conclude that
LMP2A is ubiquitinated at the amino group of amino-
terminus by Nedd4 family E3s.
Recently, amino-terminal ubiquitination has been re-
ported in studies of MyoD, LMP1, and E7, all of which are
ubiquitinated in lysine-less mutants (Aviel et al., 2000;
Breitschopf et al., 1998; Reinstein et al., 2000). For all
three proteins, deletion mutations and a Myc-tag inser-
tion at amino-terminus blocked ubiquitination and their
subsequent degradation. Similar to LMP2A, EBV-en-
coded LMP1 is a multiple membrane spanning protein
that lacks a significant extracellular domain and both the
amino- and the carboxy-terminus are localized within
cytosol. LMP2A is targeted to the membrane rafts where
it associates in characteristic patches (Longnecker and
Kieff, 1990). LMP1 and LMP2A colocalize within these
membrane patches in the EBV latent infected cells
(Longnecker and Kieff, 1990). Having similar structure, it
is of interest to note that both LMP1 and LMP2A are
ubiquitinated at the amino-terminus, indicating that EBV
may exploit this particular host cell modification, al-
though LMP1 does not appear to use Nedd4-family E3s
in its ubiquitination (Aviel et al., 2000; Ikeda et al., 2001).
It is still unclear whether amino-terminal ubiquitination is
a general modification for most proteins. This awaits the
construction of mutations in other cellular and viral pro-
teins in which all the lysines have been mutated to
alternate amino acids. In addition, other modifications
such as acetylation at the amino-terminus of proteins
may prevent amino-terminal ubiquitination. Acetylation is
the most common form of cotranslational chemical mod-
ification involving approximately 85% of all proteins
(Driessen et al., 1985). Further study is clearly warranted.
In addition, the influence of phosphorylation for ubiquiti-
nation and degradation varies between LMP2A and
LMP1. LMP1 is phosphorylated primarily on serine but
also on threonine residues and this phosphorylation is
required for LMP1 ubiquitination (Aviel et al., 2000).
LMP2A is highly tyrosine phosphorylated, but in contrast
to LMP1, this phosphorylation is not required for LMP2A
ubiquitination. Mutation of tyrosine 112 to phenylalanine
in LMP2A results in a complete absence of LMP2A
tyrosine phosphorylation (Fruehling et al., 1998), and this
mutant is ubiquitinated similar to wild-type LMP2A (data
not shown).
We found that the predominant form of LMP2A ex-
pressed in EBV immortalized lymphocytes begins at me-
thionine 6 in the LMP2A protein sequence as long as the
posttranslational modification of LMP2A is similar in both
LCLs and BJAB cells. This form of LMP2A, in comparison
to LMP2A beginning at methionine 9 or a mutant form of
LMP2A with a Myc-Tag inserted immediately after me-
thionine 1, was not as highly ubiquitinated, indicating that
the sequence context or microenvironment of the amino-
terminal domain is important in the ubiquitination of
LMP2A. By analyzing the amino acid sequence of amino-
terminus, we found that LMP2A contains along with the
methionine two additional hydrophobic amino acids at its
amino-terminus. This hydrophobicity is conserved in dif-
ferent -herpesviruses (Franken et al., 1995; Rivailler et
al., 1999) and EBV clinical isolates (Busson et al., 1995).
It is too short to span the plasma membrane; however, it
may still be able to interact with the plasma membrane,
another region of the LMP2A, another protein, or it may
contain a specific signal required for LMP2A ubiquitina-
tion. Thus changes in this amino-terminal region of
LMP2A, as shown in this study, may dramatically alter
the amount of LMP2A ubiquitination.
Finally, a conformational change might also be re-
quired for the efficient LMP2A ubiquitination. A recent
NMR study elucidating the tertiary structure of Nedd4
WW domain associating with ENaC PY motif peptide
revealed that binding of Nedd4 WW domain leads a
sharp -turn at a leucine residue adjacent to the PY motif
(Kanelis et al., 2001), indicating that Nedd4 binding in-
duces a conformational change in the substrate protein.
LMP2A ubiquitination likely plays a role in modulating
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the signaling capacity of LMP2A complexes within the
plasma membrane of latently infected cells. We have
previously shown that mutation of the LMP2A PY motifs,
responsible for binding the Nedd4-family ubiquitin-pro-
tein ligases, results in a dramatic increase in the phos-
phorylation of signaling proteins involved in LMP2A sig-
nal transduction. Further investigation of the amino-ter-
minal ubiquitination of LMP2A by the construction of
mutants with altered ubiquitination may provide clues to
the mechanism and functional significance of amino-
terminal ubiquitination.
MATERIALS AND METHODS
Antibodies
Rat monoclonal antibody against LMP2A (14B7) was
described previously (Fruehling et al., 1996). Mouse
monoclonal antibody against FLAG tag (M2) was from
Sigma. Mouse monoclonal antibody against HA tag (HA.
11) was from Covance. All horseradish peroxidase
(HRP)-conjugated secondary antibodies were purchased
from Amersham.
Plasmids
The wild-type LMP2A cDNA was subcloned into
EcoRI-BgIII site of the mammal expression vector pSG5.
The PY1PY2, Lysine-less, M1, M6, M9, Myc, and His
LMP2A expression constructs were made using stan-
dard cloning strategies as described previously (Ikeda et
al., 2000). Each construct contains the same upstream
sequence from the initiating ATG along with a perfectly
matched Kozak sequence to insure that each construct
translates equivalent amounts of LMP2A. The FLAG-
tagged AIP4 and WWP2 cDNA, subcloned into the mam-
mal expression vector pcDNA3.1 Neo, was described
previously (Ikeda et al., 2000). C823A mutation at an
active-site cysteine of the WWP2 HECT domain was also
produced using a PCR-based strategy. HA-tagged ubiq-
uitin (Ub-HA) expression plasmid was provided by Dr. D.
Bohmann (Treier et al., 1994).
Cell culture and transient transfections
BJAB is an EBV negative B lyphoma cell line obtained
from ATCC (Rockville, MD). The generation of LCLs was
described elsewhere (Fruehling et al., 1996). All cell lines
were maintained in RPMI1640 medium supplemented
with 10% fetal bovine serum (FBS), 1000 U/ml penicillin,
and 1000 g/ml streptomycin. BJAB cells (1  107 cells)
were transiently transfected with Gene Pulser (Bio-Rad)
at 210 V and 960 F capacitance and were analyzed after
24 h.
Detection of ubiquitin conjugates
BJAB cells were transiently transfected with 20 g of
LMP2A expression plasmid, 10 g of E3 expression
plasmid, and 10 g of HA-tagged ubiquitin expression
plasmid. Following culture, the cells were harvested and
lysed in 0.5 ml of 1 PBS containing 1% SDS to prevent
deubiquitination and minimize nonspecific protein–pro-
tein association. After sonication, lysates were adjusted
to 1 ml with 50 mM Tris–HCl pH 7.5, 150 mM NaCl, 1%
Triton X-100, 0.5% SDS, 0.25% deoxycholic acid, 10%
glycerol, 10 mM NaF, 1 mM Na3VO4, 2mM EDTA, 0.5 mM
phenylmethylsulfonyl fluoride, 10 g/ml pepstatin, and 10
g/ml leupeptin. Cleared lysates were incubated with
the appropriate antibody for 1 h at 4°C. Immune com-
plexes were captured with 20 l of Protein A or G-
Sepharose (Pharmacia) for 1 h at 4°C. Following three
washes with lysis buffer, immunoprecipitated proteins
were resuspended in 2 SDS–PAGE sample buffer. Pro-
tein samples were resolved by SDS–PAGE, transferred to
Immobilon, and blocked with 4% skim milk at room tem-
perature for 1 h. Membranes were then incubated in 4%
skim milk in TBST (10 mM Tris–HCl pH 7.5, 150 mM NaCl,
0.05% Tween 20) with primary antibody for 1 h, and then
with appropriate secondary antibody for 1 h. The blot
was visualized using ECL (Amersham).
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